cilostazol has been researched along with Apoplexy in 134 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 9.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "In the Cilostazol Stroke Prevention Study combination trial, patients with high-risk, non-cardioembolic ischemic stroke between 8 and 180 days after onset treated with aspirin or clopidogrel alone were recruited and randomly assigned to receive either monotherapy or dual antiplatelet therapy (DAPT) using cilostazol and followed up for 0." | 9.69 | Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com. ( Hoshino, H; Kimura, K; Minematsu, K; Omae, K; Origasa, H; Takahashi, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 9.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "Long-term treatment with the combination of cilostazol with aspirin or clopidogrel showed a lower risk of stroke recurrence compared to aspirin or clopidogrel alone after high-risk noncardioembolic ischemic stroke in a randomized trial." | 9.51 | Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. ( Hoshino, H; Ihara, M; Kimura, K; Kitagawa, K; Koga, M; Minematsu, K; Miwa, K; Omae, K; Suda, Y; Toru, S; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2022) |
| "We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF." | 9.34 | Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 9.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "Background The aim of the present study was to investigate the efficacy and safety of antiplatelet (aspirin plus cilostazol) dual therapy for patients with noncardioembolic stroke within 48 hours of symptom onset." | 9.30 | Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2019) |
| "Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with aspirin and cilostazol for prevention of secondary stroke, but the physiological mechanism involved remains unknown." | 9.24 | Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study. ( Kohara, S; Ohnuki, Y; Shimizu, M; Takizawa, S, 2017) |
| "This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease." | 9.20 | The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015) |
| "Adult patients with noncardioembolic ischemic stroke within 24 hours after onset were randomized to receive cilostazol 200 mg/day (cilostazol group) or no medication (control group) in addition to the optimum medical treatments (a free radical scavenger plus an antiplatelet agent or an antithrombin agent)." | 9.17 | Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. ( Kayama, T; Mizoi, K; Mori, E; Ogasawara, K; Ogawa, A; Saito, K; Shimizu, H; Terayama, Y; Tominaga, T, 2013) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 9.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 9.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "Cilostazol appeared to have beneficial effects in poststroke patients with cerebral ischemia and might improve cerebral circulation and rehabilitation outcome." | 9.15 | Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2011) |
| "Aspirin is a proven antiplatelet agent in acute ischemic stroke, and there are no current guidelines for other antiplatelet treatments." | 9.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 9.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "Patients aged 20-79 years who had had a cerebral infarction within the previous 26 weeks were enrolled at 278 sites in Japan and allocated to receive 100 mg cilostazol twice daily or 81 mg aspirin once daily for 1-5 years." | 9.14 | Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2010) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 9.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "gov were searched from inception to 25 September 2020, for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo, in patients with ischaemic stroke." | 9.12 | Cilostazol for secondary stroke prevention: systematic review and meta-analysis. ( Chan, BP; Leow, AS; Sharma, VK; Sia, CH; Tan, BY; Tan, CH; Wu, AG; Yeo, LL, 2021) |
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 9.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "A systematic review and meta-analysis of unconfounded randomized controlled trials of cilostazol to prevent stroke, cognitive decline, or radiological small vessel disease lesion progression." | 9.05 | Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis. ( Appleton, JP; Bath, PM; Blair, GW; Chappell, FM; Doubal, F; McHutchison, C; Wardlaw, JM, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| " Stroke recurrence (including hemorrhagic and ischemic) with cilostazol use was 5." | 8.91 | Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis. ( Cao, L; Feng, H; Hu, R; Margaret, B; Tan, L; Yin, Y; Zhang, JH; Zhang, Y, 2015) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 8.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 8.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke." | 8.89 | Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. ( Bangalore, S; Dinicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; Messerli, FH; O'Keefe, JH, 2013) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 8.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "To evaluate the safety and efficacy of cilostazol for secondary prevention of non-cardioembolic ischemic stroke." | 8.88 | Use of cilostazol for secondary stroke prevention: an old dog with new tricks? ( Ansara, AJ; Shiltz, DL; Slavens, JB, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 8.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| "We compared the efficacy and safety of cilostazol and aspirin in 2,672 Japanese patients with non-cardioembolic ischemic stroke." | 8.86 | [Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients]. ( Uchiyama, S, 2010) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 8.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "Background The objective of the study was to assess the cost-effectiveness of cilostazol (a selective phosphodiesterase 3 inhibitor) added to aspirin or clopidogrel for secondary stroke prevention in patients with noncardioembolic stroke." | 8.12 | Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. ( de Havenon, A; Kraler, L; Lansberg, MG; Zhou, LW, 2022) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 7.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| "The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS)." | 7.85 | Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2017) |
| "Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis." | 7.83 | Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2016) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 7.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Our objective was to investigate the effect of cilostazol in acute therapy for small vessel stroke patients." | 7.80 | The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction. ( Nakase, T; Sasaki, M; Suzuki, A, 2014) |
| "The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25." | 7.80 | Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2014) |
| "Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients." | 7.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "9 years) with ischemic stroke or carotid artery stenting who received clopidogrel (75 mg) for >7 days at our hospital between October 2009 and March 2010." | 7.77 | Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay. ( Deguchi, I; Dembo, T; Fukuoka, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagoya, H; Takeda, H; Tanahashi, N, 2011) |
| " The involvement or otherwise of the phenotypic modulation of SMCs in cerebral small-vessel pathology has been investigated, and the effect of cilostazol on both the small vessels and the WM lesions has been determined in stroke-prone spontaneously hypertensive rats (SHRSP)." | 7.74 | Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats. ( Fujita, Y; Lin, JX; Takahashi, R; Tomimoto, H, 2008) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 7.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 6.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| "Cilostazol is a PDE3 (phosphodiesterase III) inhibitor with a long track record of safety that is Food and Drug Administration and European Medicines Agency approved for the treatment of claudication in patients with peripheral arterial disease." | 6.72 | Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. ( de Havenon, A; Elm, JJ; Johnston, KC; Johnston, SC; Lansberg, MG; Madsen, TE; Sheth, KN; Shoamanesh, A; Toyoda, K; Turan, TN; Wardlaw, JM; Williams, OA, 2021) |
| "Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including antiplatelet and vasodilatation effects and protective effects on endothelial cells." | 6.53 | Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives. ( Hara, H; Takagi, T, 2016) |
| "Cilostazol, by contrast, has been shown to significantly reduce the risk of recurrent strokes without affecting the occurrence of intracranial hemorrhage." | 6.43 | Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. ( Matsumoto, M, 2005) |
| "A previous randomized study showed that dual antiplatelet therapy (DAPT) with aspirin and cilostazol is not superior to aspirin monotherapy for patients with acute non-cardioembolic stroke; however, the reason for this remains uncertain." | 5.69 | Tachycardia Changes Increase Neurological Deterioration in Patients with Acute Non-Cardioembolic Stroke: An ADS Post-Hoc Analysis. ( Aoki, J; Fujimoto, S; Kimura, K; Matsuzono, K; Ozawa, T, 2023) |
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 5.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "In the Cilostazol Stroke Prevention Study combination trial, patients with high-risk, non-cardioembolic ischemic stroke between 8 and 180 days after onset treated with aspirin or clopidogrel alone were recruited and randomly assigned to receive either monotherapy or dual antiplatelet therapy (DAPT) using cilostazol and followed up for 0." | 5.69 | Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com. ( Hoshino, H; Kimura, K; Minematsu, K; Omae, K; Origasa, H; Takahashi, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 5.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilostazol treatment on vascular, functional, and cognitive outcomes in patients with lacunar stroke." | 5.69 | Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial. ( Bamford, J; Bath, PM; Cvoro, V; Doubal, FN; England, T; Hassan, A; Heye, AK; Mhlanga, II; Montgomery, A; O'Brien, JT; Oatey, K; Roffe, C; Sprigg, N; Wardlaw, JM; Werring, DJ; Woodhouse, LJ, 2023) |
| "Long-term treatment with the combination of cilostazol with aspirin or clopidogrel showed a lower risk of stroke recurrence compared to aspirin or clopidogrel alone after high-risk noncardioembolic ischemic stroke in a randomized trial." | 5.51 | Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. ( Hoshino, H; Ihara, M; Kimura, K; Kitagawa, K; Koga, M; Minematsu, K; Miwa, K; Omae, K; Suda, Y; Toru, S; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2022) |
| "Cilostazol was more frequently used in the SAP(-) group (20." | 5.48 | Cilostazol is Effective to Prevent Stroke-Associated Pneumonia in Patients Receiving Tube Feeding. ( Mizuma, A; Nagata, E; Netsu, S; Sakamoto, M; Takizawa, S; Yutani, S, 2018) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 5.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively." | 5.34 | Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020) |
| "We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF." | 5.34 | Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 5.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "Background The aim of the present study was to investigate the efficacy and safety of antiplatelet (aspirin plus cilostazol) dual therapy for patients with noncardioembolic stroke within 48 hours of symptom onset." | 5.30 | Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2019) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| "Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with aspirin and cilostazol for prevention of secondary stroke, but the physiological mechanism involved remains unknown." | 5.24 | Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study. ( Kohara, S; Ohnuki, Y; Shimizu, M; Takizawa, S, 2017) |
| " The PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage-Intima-Media Thickness (PICASSO-IMT) sub-study is designed to investigate the effects of cilostazol, probucol, or both on IMT in patients with stroke." | 5.24 | Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study. ( Kim, YJ; Kwon, SU; Lee, J; Seo, WK, 2017) |
| "Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications." | 5.22 | Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications. ( Manolis, AA; Manolis, AS; Manolis, TA; Melita, H; Mikhailidis, DP, 2022) |
| " Search terms included ischemic stroke, aspirin, clopidogrel, dipyridamole, ticagrelor, cilostazol, prasugrel, glycoprotein IIb/IIIa inhibitors." | 5.22 | Antiplatelet Use in Ischemic Stroke. ( Ali, A; Baig, S; Bell, SM; Kamarova, M; Majid, A; Monks, K; Patel, H; Redgrave, J; Wasay, M, 2022) |
| "Primarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone derivative that works through the inhibition of phosphodiesterase III and related increases in cyclic adenosine monophosphate (cAMP) levels." | 5.22 | Cilostazol: a Review of Basic Mechanisms and Clinical Uses. ( Angiolillo, D; Birnbaum, Y; Khawaja, M; Kherallah, RY; Olson, M, 2022) |
| " This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function." | 5.22 | Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage. ( Hong, KS; Kwon, SU; Lee, J; Lee, JS; Oh, MS; Yu, KH, 2016) |
| "This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease." | 5.20 | The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015) |
| "PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage was designed to compare cilostazol and aspirin and to assess the effect of adding probucol, a lipid-lowering and anti-oxidative agent, in patients at high risk of haemorrhagic stroke." | 5.20 | Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial. ( Hong, KS; Kim, BJ; Kwon, SU; Lee, JY, 2015) |
| "We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke." | 5.19 | Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014) |
| "Adult patients with noncardioembolic ischemic stroke within 24 hours after onset were randomized to receive cilostazol 200 mg/day (cilostazol group) or no medication (control group) in addition to the optimum medical treatments (a free radical scavenger plus an antiplatelet agent or an antithrombin agent)." | 5.17 | Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. ( Kayama, T; Mizoi, K; Mori, E; Ogasawara, K; Ogawa, A; Saito, K; Shimizu, H; Terayama, Y; Tominaga, T, 2013) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 5.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 5.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "Cilostazol appeared to have beneficial effects in poststroke patients with cerebral ischemia and might improve cerebral circulation and rehabilitation outcome." | 5.15 | Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2011) |
| "Aspirin is a proven antiplatelet agent in acute ischemic stroke, and there are no current guidelines for other antiplatelet treatments." | 5.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 5.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "Patients aged 20-79 years who had had a cerebral infarction within the previous 26 weeks were enrolled at 278 sites in Japan and allocated to receive 100 mg cilostazol twice daily or 81 mg aspirin once daily for 1-5 years." | 5.14 | Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2010) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 5.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "gov were searched from inception to 25 September 2020, for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo, in patients with ischaemic stroke." | 5.12 | Cilostazol for secondary stroke prevention: systematic review and meta-analysis. ( Chan, BP; Leow, AS; Sharma, VK; Sia, CH; Tan, BY; Tan, CH; Wu, AG; Yeo, LL, 2021) |
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 5.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "A systematic review and meta-analysis of unconfounded randomized controlled trials of cilostazol to prevent stroke, cognitive decline, or radiological small vessel disease lesion progression." | 5.05 | Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis. ( Appleton, JP; Bath, PM; Blair, GW; Chappell, FM; Doubal, F; McHutchison, C; Wardlaw, JM, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "Cilostazol seems to decrease total ISR rates in patients undergoing CAS without affecting MI/stroke/death events, both in the early and late settings." | 4.93 | Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting. ( Aggeli, K; Filis, K; Galyfos, G; Geropapas, G; Sianou, A; Sigala, F, 2016) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| " Stroke recurrence (including hemorrhagic and ischemic) with cilostazol use was 5." | 4.91 | Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis. ( Cao, L; Feng, H; Hu, R; Margaret, B; Tan, L; Yin, Y; Zhang, JH; Zhang, Y, 2015) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 4.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 4.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "The role of aspirin in the early management of stroke is well established." | 4.89 | Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013) |
| "Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke." | 4.89 | Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. ( Bangalore, S; Dinicolantonio, JJ; Fares, H; Lavie, CJ; Menezes, AR; Messerli, FH; O'Keefe, JH, 2013) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 4.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "To evaluate the safety and efficacy of cilostazol for secondary prevention of non-cardioembolic ischemic stroke." | 4.88 | Use of cilostazol for secondary stroke prevention: an old dog with new tricks? ( Ansara, AJ; Shiltz, DL; Slavens, JB, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 4.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "We compared the efficacy and safety of cilostazol and aspirin in 2,672 Japanese patients with non-cardioembolic ischemic stroke." | 4.86 | [Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients]. ( Uchiyama, S, 2010) |
| "Patients who participated in the Acute Aspirin Plus Cilostazol Dual Therapy for Non-cardiogenic Stroke Patients Within 48 Hours of Symptom Onset (ADS) trial were included in this study." | 4.31 | Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis. ( Aoki, J; Fujimoto, S; Kimura, K; Matsuzono, K; Ozawa, T, 2023) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 4.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "Background The objective of the study was to assess the cost-effectiveness of cilostazol (a selective phosphodiesterase 3 inhibitor) added to aspirin or clopidogrel for secondary stroke prevention in patients with noncardioembolic stroke." | 4.12 | Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. ( de Havenon, A; Kraler, L; Lansberg, MG; Zhou, LW, 2022) |
| "Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients." | 4.02 | Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2021) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 3.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| "The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS)." | 3.85 | Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2017) |
| "Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD." | 3.83 | Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. ( Aoyama, T; Ishii, H; Ito, Y; Kamoi, D; Kumada, Y; Murohara, T; Sakakibara, T; Suzuki, S; Takahashi, H; Tanaka, A; Umemoto, N, 2016) |
| "Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis." | 3.83 | Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2016) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 3.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Our objective was to investigate the effect of cilostazol in acute therapy for small vessel stroke patients." | 3.80 | The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction. ( Nakase, T; Sasaki, M; Suzuki, A, 2014) |
| "The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25." | 3.80 | Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. ( Genka, C; Hamada, C; Handa, S; Katayama, Y; Kitagawa, Y; Koretsune, Y; Kusuoka, H; Matsuoka, K; Nishimaru, K; Ohashi, Y; Sawada, T; Shinohara, Y; Tanahashi, N; Tsushima, M; Uchiyama, S; Yamaguchi, T; Yamamoto, H, 2014) |
| "Cilostazol increases the walking distance in patients with intermittent claudication, but there is scarce evidence of any effect on the risk for subsequent ischemic events, bleeding or death." | 3.80 | Cilostazol and outcome in outpatients with peripheral artery disease. ( Aguilar, E; Esteban, C; Jiménez Caballero, PE; Manzano, L; Monreal, M; Mujal, A; Perez, P; Sánchez Muñoz-Torrero, JF; Sauquillo, JC; Yeste, M, 2014) |
| " He was thought to have had an embolic stroke and was initially treated with warfarin." | 3.80 | Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014) |
| "Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients." | 3.79 | Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "9 years) with ischemic stroke or carotid artery stenting who received clopidogrel (75 mg) for >7 days at our hospital between October 2009 and March 2010." | 3.77 | Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay. ( Deguchi, I; Dembo, T; Fukuoka, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagoya, H; Takeda, H; Tanahashi, N, 2011) |
| " The aim of the present study is to investigate the effects of cilostazol and aspirin on endothelial nitric oxide synthase (eNOS) phosphorylation in the cerebral cortex, endothelial function, and infarct size after brain ischemia in spontaneously hypertensive rats (SHR)." | 3.77 | Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. ( Kawamura, M; Kitagawa, K; Omura-Matsuoka, E; Oyama, N; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2011) |
| " The involvement or otherwise of the phenotypic modulation of SMCs in cerebral small-vessel pathology has been investigated, and the effect of cilostazol on both the small vessels and the WM lesions has been determined in stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.74 | Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats. ( Fujita, Y; Lin, JX; Takahashi, R; Tomimoto, H, 2008) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 3.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "Prior intracerebral hemorrhage (ICH) is associated with increased risk of ischemic stroke." | 3.01 | Prior intracerebral hemorrhage and white matter hyperintensity burden on recurrent stroke risk. ( Heo, SH; Kwon, HS; Kwon, SU; Park, JH, 2021) |
| "Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease." | 3.01 | Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions. ( Abedi, A; Choi, W; Nguyen, VN; Rennert, RC; Russin, JJ; Sizdahkhani, S, 2023) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction and ischemic stroke at 6 months after PCI." | 2.76 | Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. ( Bae, JH; Bae, JW; Chae, IH; Cho, MC; Kim, HS; Lee, SP; Park, KW; Rha, SW; Suh, JW, 2011) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 2.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| "Cilostazol is a PDE3 (phosphodiesterase III) inhibitor with a long track record of safety that is Food and Drug Administration and European Medicines Agency approved for the treatment of claudication in patients with peripheral arterial disease." | 2.72 | Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. ( de Havenon, A; Elm, JJ; Johnston, KC; Johnston, SC; Lansberg, MG; Madsen, TE; Sheth, KN; Shoamanesh, A; Toyoda, K; Turan, TN; Wardlaw, JM; Williams, OA, 2021) |
| "Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including antiplatelet and vasodilatation effects and protective effects on endothelial cells." | 2.53 | Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives. ( Hara, H; Takagi, T, 2016) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Stroke is the second cause of mortality worldwide, and intravenous administration of tissue plasminogen activator (t-PA) within 3 h of symptom onset is the only treatment proven effective for re-establishment of cerebral blood flow following acute ischemic stroke." | 2.47 | Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke. ( Hara, H; Shimazawa, M, 2011) |
| "Intracranial arterial stenosis (IAS) is the cause of about 10% of all ischemic strokes in the United States, but may account for about 40% of strokes in some populations." | 2.47 | Current management of symptomatic intracranial stenosis. ( Kasner, SE; Taylor, RA; Weigele, JB, 2011) |
| "In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours." | 2.46 | [New clinical concept and therapeutic strategy for TIA]. ( Urabe, T, 2010) |
| "The key areas of treatment focus on smoking cessation, exercise rehabilitation, with supervised therapy if possible, cardiovascular risk prevention with antiplatelet drugs, statins and angiotensin converting enzymes, and correction of atherosclerotic risk factors with well-defined targets (LDL less than 1g/L, HDL greater than 0." | 2.45 | [Peripheral arterial disease with lower limb claudication: Medical treatment]. ( Bui, HT; Hadj Henni, A; Journet, J; Long, A, 2009) |
| "Cilostazol has been shown to be of benefit in improving walking distance in people with IC." | 2.44 | Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2007) |
| "Cilostazol has been shown to be of benefit in improving walking distance in people with IC." | 2.44 | Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2008) |
| "Cilostazol, by contrast, has been shown to significantly reduce the risk of recurrent strokes without affecting the occurrence of intracranial hemorrhage." | 2.43 | Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. ( Matsumoto, M, 2005) |
| "Cilostazol was developed as a selective inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3)." | 2.43 | Cilostazol: therapeutic potential against focal cerebral ischemic damage. ( Hong, KW; Kima, KY; Lee, JH; Lee, WS; Park, SY, 2006) |
| "Cilostazol was marketed first in Japan in 1988 and later in seven other countries for the treatment of chronic arterial occlusion." | 2.41 | [Research and development of cilostazol: an antiplatelet agent]. ( Kimura, Y; Nakagawa, K; Nishi, T, 2000) |
| "Cilostazol has also been reported to inhibit smooth muscle cell proliferation in vitro and has been demonstrated in a clinical study to favorably alter plasma lipids: to decrease triglyceride and to increase HDL-cholesterol levels." | 2.41 | Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. ( Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M, 2001) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "Methods- Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in 6- to 8-week-old male C57Bl/6 wild-type mice receiving substance V or vehicle 1 hour after ischemia induction." | 1.51 | Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function. ( Bieber, M; Kleinschnitz, C; Kraft, P; Kumar, GJ; Nieswandt, B; Pham, M; Schuhmann, MK; Stoll, G; Vaidya, JR; Volz, J, 2019) |
| "Cilostazol was more frequently used in the SAP(-) group (20." | 1.48 | Cilostazol is Effective to Prevent Stroke-Associated Pneumonia in Patients Receiving Tube Feeding. ( Mizuma, A; Nagata, E; Netsu, S; Sakamoto, M; Takizawa, S; Yutani, S, 2018) |
| "Cilostazol is an antiplatelet drug often used in Asian countries like Korea, Japan, and China." | 1.42 | Cilostazol research in Asia: can it be applied to European and American patients? ( Kim, JS; Kwon, SU; Uchiyama, S, 2015) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 1.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation." | 1.36 | Cilostazol reduces restenosis after carotid artery stenting. ( Hayakawa, M; Matsumaru, Y; Matsumura, A; Nemoto, S; Takigawa, T, 2010) |
| "However, the ratio of stroke to ischemic heart disease is still different between the East and West." | 1.33 | Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? ( Shinohara, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (14.93) | 29.6817 |
| 2010's | 78 (58.21) | 24.3611 |
| 2020's | 36 (26.87) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JH | 3 |
| Kwon, SU | 11 |
| Kwon, HS | 2 |
| Heo, SH | 4 |
| de Havenon, A | 3 |
| Sheth, KN | 1 |
| Madsen, TE | 2 |
| Johnston, KC | 1 |
| Turan, TN | 1 |
| Toyoda, K | 8 |
| Elm, JJ | 1 |
| Wardlaw, JM | 5 |
| Johnston, SC | 1 |
| Williams, OA | 1 |
| Shoamanesh, A | 1 |
| Lansberg, MG | 2 |
| Uchiyama, S | 13 |
| Omae, K | 4 |
| Saita, R | 1 |
| Kimura, K | 13 |
| Hoshino, H | 7 |
| Sakai, N | 3 |
| Okada, Y | 7 |
| Tanaka, K | 2 |
| Origasa, H | 5 |
| Naritomi, H | 4 |
| Houkin, K | 3 |
| Yamaguchi, K | 5 |
| Isobe, M | 2 |
| Minematsu, K | 7 |
| Matsumoto, M | 3 |
| Tominaga, T | 4 |
| Tomimoto, H | 3 |
| Terayama, Y | 3 |
| Yasuda, S | 2 |
| Yamaguchi, T | 10 |
| Manolis, AA | 1 |
| Manolis, TA | 1 |
| Melita, H | 1 |
| Mikhailidis, DP | 6 |
| Manolis, AS | 1 |
| Miwa, K | 1 |
| Suda, Y | 1 |
| Toru, S | 1 |
| Kitagawa, K | 4 |
| Ihara, M | 1 |
| Koga, M | 1 |
| Kamarova, M | 1 |
| Baig, S | 1 |
| Patel, H | 1 |
| Monks, K | 1 |
| Wasay, M | 1 |
| Ali, A | 1 |
| Redgrave, J | 1 |
| Majid, A | 1 |
| Bell, SM | 1 |
| Matsuzono, K | 2 |
| Fujimoto, S | 6 |
| Aoki, J | 6 |
| Ozawa, T | 2 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Zhou, LW | 1 |
| Kraler, L | 1 |
| Shirai, Y | 1 |
| Toi, S | 1 |
| Adachi, U | 1 |
| Tsutsumi, Y | 1 |
| Okamura, S | 1 |
| Takahashi, K | 2 |
| Bath, PM | 3 |
| Mhlanga, I | 1 |
| Woodhouse, LJ | 2 |
| Doubal, F | 2 |
| Oatey, K | 2 |
| Montgomery, AA | 1 |
| Jung, SJ | 1 |
| Shim, SR | 1 |
| Kim, BJ | 6 |
| Jung, JM | 4 |
| Liu, H | 1 |
| Shao, T | 1 |
| Yang, T | 1 |
| Li, D | 1 |
| Wang, H | 1 |
| Cheng, Y | 3 |
| Zhang, T | 1 |
| Zhang, J | 2 |
| Hou, X | 1 |
| Cen, K | 1 |
| Cui, Y | 1 |
| Zhang, Y | 3 |
| Feng, X | 1 |
| Nishiyama, Y | 1 |
| Otsuka, T | 1 |
| Mhlanga, II | 1 |
| Heye, AK | 1 |
| Bamford, J | 1 |
| Cvoro, V | 1 |
| Doubal, FN | 2 |
| England, T | 1 |
| Hassan, A | 1 |
| Montgomery, A | 1 |
| O'Brien, JT | 1 |
| Roffe, C | 1 |
| Sprigg, N | 1 |
| Werring, DJ | 1 |
| Lee, YJ | 1 |
| Je, NK | 1 |
| Abedi, A | 1 |
| Sizdahkhani, S | 1 |
| Choi, W | 1 |
| Nguyen, VN | 1 |
| Rennert, RC | 1 |
| Russin, JJ | 1 |
| Kim, SM | 1 |
| Lee, JS | 6 |
| Lee, D | 1 |
| Lee, MH | 1 |
| Yu, S | 3 |
| Lim, JS | 1 |
| Yu, KH | 2 |
| Oh, MS | 2 |
| Hong, KS | 6 |
| Lee, EJ | 2 |
| Kang, DW | 5 |
| Hankey, GJ | 2 |
| Kim, YJ | 3 |
| Wong, LKS | 2 |
| Hwang, YH | 2 |
| Lee, J | 4 |
| Rha, JH | 3 |
| Ahn, SH | 2 |
| Seo, WK | 3 |
| Park, JM | 3 |
| Lee, JH | 7 |
| Kwon, JH | 2 |
| Sohn, SI | 2 |
| Navarro, JC | 2 |
| Kim, HY | 1 |
| Kim, EG | 1 |
| Kim, S | 2 |
| Cha, JK | 2 |
| Park, MS | 1 |
| Nam, HS | 1 |
| Iguchi, Y | 4 |
| Urabe, T | 5 |
| Yamagami, H | 4 |
| Todo, K | 4 |
| Idomari, K | 4 |
| Kaneko, N | 4 |
| Iwanaga, T | 4 |
| Terasaki, T | 4 |
| Tanaka, R | 4 |
| Yamamoto, N | 4 |
| Tsujino, A | 5 |
| Nomura, K | 4 |
| Abe, K | 5 |
| Uno, M | 4 |
| Matsuoka, H | 4 |
| Yamagata, S | 4 |
| Yamamoto, Y | 4 |
| Yonehara, T | 4 |
| Inoue, T | 4 |
| Yagita, Y | 5 |
| McHutchison, C | 1 |
| Blair, GW | 1 |
| Appleton, JP | 1 |
| Chappell, FM | 1 |
| Yuan, HW | 1 |
| Lin, YJ | 1 |
| Ji, RJ | 1 |
| Blair, G | 1 |
| Xu, T | 1 |
| Wang, Y | 1 |
| Chen, Y | 1 |
| Tan, CH | 1 |
| Wu, AG | 1 |
| Sia, CH | 1 |
| Leow, AS | 1 |
| Chan, BP | 1 |
| Sharma, VK | 1 |
| Yeo, LL | 1 |
| Tan, BY | 1 |
| Kherallah, RY | 1 |
| Khawaja, M | 1 |
| Olson, M | 1 |
| Angiolillo, D | 1 |
| Birnbaum, Y | 1 |
| Brown, T | 1 |
| Forster, RB | 1 |
| Cleanthis, M | 2 |
| Stansby, G | 3 |
| Stewart, M | 2 |
| Ohnuki, Y | 2 |
| Kohara, S | 1 |
| Shimizu, M | 1 |
| Takizawa, S | 2 |
| Lee, CH | 1 |
| Lee, JY | 2 |
| Park, GM | 1 |
| Lee, SW | 1 |
| Kim, HS | 5 |
| Choi, YJ | 1 |
| Nam, CW | 1 |
| Cho, JH | 1 |
| Shin, WY | 1 |
| Seo, JB | 1 |
| Choi, SW | 1 |
| Min, PK | 1 |
| Her, SH | 1 |
| Lee, PH | 1 |
| Ahn, JM | 1 |
| Park, DW | 1 |
| Kang, SJ | 1 |
| Kim, YH | 1 |
| Lee, CW | 1 |
| Park, SW | 1 |
| Park, SJ | 1 |
| Netsu, S | 1 |
| Mizuma, A | 1 |
| Sakamoto, M | 1 |
| Yutani, S | 1 |
| Nagata, E | 1 |
| Wu, Z | 1 |
| Liu, AF | 1 |
| Zhou, J | 1 |
| Wang, K | 1 |
| Li, C | 2 |
| Qiu, H | 1 |
| Jiang, WJ | 1 |
| Choi, PK | 1 |
| Chung, JY | 1 |
| Lee, SJ | 3 |
| Kang, HG | 1 |
| Bieber, M | 1 |
| Schuhmann, MK | 1 |
| Volz, J | 1 |
| Kumar, GJ | 1 |
| Vaidya, JR | 1 |
| Nieswandt, B | 1 |
| Pham, M | 1 |
| Stoll, G | 1 |
| Kleinschnitz, C | 1 |
| Kraft, P | 1 |
| Hill, MD | 1 |
| Benavente, OR | 1 |
| Easton, JD | 2 |
| Lee, WH | 1 |
| Chu, CY | 1 |
| Hsu, PC | 1 |
| Su, HM | 1 |
| Lin, TH | 1 |
| Voon, WC | 1 |
| Lai, WT | 1 |
| Sheu, SH | 1 |
| Shimizu, H | 2 |
| Ogawa, A | 1 |
| Kayama, T | 1 |
| Mizoi, K | 1 |
| Saito, K | 1 |
| Ogasawara, K | 1 |
| Mori, E | 1 |
| Watson, A | 1 |
| Apostolakis, S | 1 |
| Lip, GY | 1 |
| Shantsila, E | 1 |
| Dinicolantonio, JJ | 1 |
| Lavie, CJ | 1 |
| Fares, H | 1 |
| Menezes, AR | 1 |
| O'Keefe, JH | 1 |
| Bangalore, S | 1 |
| Messerli, FH | 1 |
| Park, KW | 3 |
| Kang, SH | 1 |
| Park, JJ | 1 |
| Yang, HM | 1 |
| Kang, HJ | 2 |
| Koo, BK | 2 |
| Park, BE | 1 |
| Cha, KS | 1 |
| Rhew, JY | 1 |
| Jeon, HK | 1 |
| Shin, ES | 1 |
| Oh, JH | 2 |
| Jeong, MH | 1 |
| Hwang, KK | 1 |
| Yoon, JH | 1 |
| Lee, SY | 1 |
| Park, TH | 1 |
| Moon, KW | 1 |
| Kwon, HM | 2 |
| Chae, IH | 3 |
| Qian, Y | 1 |
| Bi, Q | 1 |
| Omote, Y | 1 |
| Deguchi, K | 1 |
| Kono, S | 1 |
| Liu, N | 1 |
| Liu, W | 3 |
| Kurata, T | 1 |
| Yamashita, T | 1 |
| Ikeda, Y | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Lee, YS | 2 |
| Bae, HJ | 2 |
| Nakase, T | 1 |
| Sasaki, M | 1 |
| Suzuki, A | 1 |
| Song, PS | 1 |
| Song, YB | 1 |
| Yang, JH | 1 |
| Hahn, JY | 1 |
| Choi, SH | 1 |
| Choi, JH | 1 |
| Lee, SH | 2 |
| Jang, Y | 1 |
| Seung, KB | 1 |
| Gwon, HC | 1 |
| Shinohara, Y | 5 |
| Katayama, Y | 2 |
| Handa, S | 2 |
| Matsuoka, K | 2 |
| Ohashi, Y | 2 |
| Tanahashi, N | 3 |
| Yamamoto, H | 3 |
| Genka, C | 2 |
| Kitagawa, Y | 2 |
| Kusuoka, H | 2 |
| Nishimaru, K | 2 |
| Tsushima, M | 2 |
| Koretsune, Y | 2 |
| Sawada, T | 2 |
| Hamada, C | 2 |
| Chen, J | 1 |
| Meng, H | 1 |
| Xu, L | 2 |
| Liu, J | 1 |
| Kong, D | 1 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 1 |
| Eikelboom, JW | 1 |
| Perez, P | 1 |
| Esteban, C | 1 |
| Sauquillo, JC | 1 |
| Yeste, M | 1 |
| Manzano, L | 1 |
| Mujal, A | 1 |
| Jiménez Caballero, PE | 1 |
| Aguilar, E | 1 |
| Sánchez Muñoz-Torrero, JF | 1 |
| Monreal, M | 1 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Bedenis, R | 1 |
| Robless, P | 3 |
| Jeng, JS | 1 |
| Sun, Y | 1 |
| Lee, JT | 1 |
| Lin, RT | 1 |
| Chen, CH | 1 |
| Po, HL | 1 |
| Lin, HJ | 1 |
| Liu, CH | 1 |
| Sun, MH | 1 |
| Sun, MC | 1 |
| Chern, CM | 1 |
| Lien, LM | 1 |
| Chiu, HC | 1 |
| Hu, HH | 1 |
| Chiou, HY | 1 |
| Chen, ST | 1 |
| Ma, H | 1 |
| Hsu, CY | 1 |
| Shi, L | 1 |
| Pu, J | 1 |
| Malaguit, J | 1 |
| Chen, S | 1 |
| Kim, JS | 2 |
| Horie, N | 1 |
| Kaminogo, M | 1 |
| Izumo, T | 1 |
| Hayashi, K | 1 |
| Nagata, I | 1 |
| Tan, L | 1 |
| Margaret, B | 1 |
| Zhang, JH | 1 |
| Hu, R | 1 |
| Yin, Y | 1 |
| Cao, L | 1 |
| Feng, H | 1 |
| Ishii, H | 1 |
| Aoyama, T | 1 |
| Takahashi, H | 1 |
| Kumada, Y | 1 |
| Kamoi, D | 1 |
| Sakakibara, T | 1 |
| Umemoto, N | 1 |
| Suzuki, S | 1 |
| Tanaka, A | 1 |
| Ito, Y | 1 |
| Murohara, T | 1 |
| Galyfos, G | 1 |
| Geropapas, G | 1 |
| Sigala, F | 1 |
| Aggeli, K | 1 |
| Sianou, A | 1 |
| Filis, K | 1 |
| Kim, YR | 2 |
| Kim, HN | 2 |
| Hong, KW | 4 |
| Shin, HK | 3 |
| Choi, BT | 2 |
| Wang, W | 1 |
| Zhang, L | 1 |
| Zhu, Q | 1 |
| Lan, Q | 1 |
| Zhao, J | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Takagi, T | 1 |
| Hara, H | 2 |
| Nakagawa, I | 1 |
| Park, HS | 1 |
| Wada, T | 1 |
| Yokoyama, S | 1 |
| Yamada, S | 1 |
| Motoyama, Y | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 1 |
| Teramoto, S | 1 |
| Yamaguchi, Y | 1 |
| Ishii, M | 1 |
| Hibi, S | 1 |
| Kume, H | 1 |
| Ouchi, Y | 1 |
| Long, A | 1 |
| Bui, HT | 1 |
| Journet, J | 1 |
| Hadj Henni, A | 1 |
| Takigawa, T | 1 |
| Matsumaru, Y | 1 |
| Hayakawa, M | 1 |
| Nemoto, S | 1 |
| Matsumura, A | 2 |
| Ha, SW | 1 |
| Guo, JJ | 1 |
| Xu, E | 3 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
| Lee, SP | 2 |
| Suh, JW | 2 |
| Lee, HY | 1 |
| Choi, DJ | 1 |
| Rha, SW | 2 |
| Bae, JW | 2 |
| Cho, MC | 2 |
| Kwon, TG | 1 |
| Bae, JH | 2 |
| Weber, R | 1 |
| Diener, HC | 1 |
| Jiang, Y | 1 |
| Xu, G | 1 |
| Liu, X | 1 |
| Kamal, AK | 4 |
| Naqvi, I | 1 |
| Husain, MR | 1 |
| Khealani, BA | 1 |
| Matsumoto, S | 1 |
| Shimodozono, M | 1 |
| Miyata, R | 1 |
| Kawahira, K | 1 |
| Khan, M | 2 |
| Maruyama, H | 1 |
| Takeda, H | 1 |
| Dembo, T | 1 |
| Nagoya, H | 1 |
| Kato, Y | 1 |
| Fukuoka, T | 1 |
| Deguchi, I | 1 |
| Horiuchi, Y | 1 |
| Shimazawa, M | 1 |
| Al-Qudah, ZA | 1 |
| Hassan, AE | 1 |
| Qureshi, AI | 1 |
| Taylor, RA | 1 |
| Weigele, JB | 1 |
| Kasner, SE | 1 |
| Yu, K | 1 |
| Cho, YJ | 1 |
| Kim, DE | 1 |
| Lee, KB | 1 |
| Koo, J | 1 |
| Han, MG | 1 |
| Jung, SW | 1 |
| Lee, BC | 1 |
| Oyama, N | 1 |
| Kawamura, M | 1 |
| Sugiyama, Y | 1 |
| Terasaki, Y | 1 |
| Omura-Matsuoka, E | 1 |
| Sasaki, T | 1 |
| Nakamura, T | 2 |
| Tsuruta, S | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Fujita, K | 1 |
| Komatsu, Y | 1 |
| Sato, N | 1 |
| Higuchi, O | 1 |
| Kujiraoka, Y | 1 |
| Kamezaki, T | 1 |
| Suzuki, K | 1 |
| Johkura, K | 1 |
| Yoshida, TN | 1 |
| Kudo, Y | 1 |
| Nakae, Y | 1 |
| Momoo, T | 1 |
| Kuroiwa, Y | 1 |
| Sidddiqi, SA | 1 |
| Ansara, AJ | 1 |
| Shiltz, DL | 1 |
| Slavens, JB | 1 |
| Hwang, KJ | 1 |
| Kim, JH | 1 |
| Chang, DI | 1 |
| Geng, DF | 1 |
| Liu, M | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Deng, J | 1 |
| Wang, JF | 1 |
| Naganuma, M | 1 |
| Isoda, K | 1 |
| Nishi, S | 1 |
| Ito, K | 1 |
| Hirano, T | 1 |
| Liu, R | 1 |
| Sun, W | 1 |
| Peng, Q | 1 |
| Zhang, W | 2 |
| Ding, M | 2 |
| Li, Y | 2 |
| Hong, Z | 2 |
| Wu, J | 2 |
| Zeng, J | 2 |
| Yao, C | 2 |
| Huang, Y | 2 |
| Kondo, R | 1 |
| Matsumoto, Y | 1 |
| Furui, E | 1 |
| Itabashi, R | 1 |
| Sato, S | 1 |
| Yazawa, Y | 1 |
| Fujiwara, S | 1 |
| Takahashi, A | 1 |
| Sukekawa, T | 1 |
| Osanai, T | 1 |
| Nishizaki, F | 1 |
| Metoki, N | 1 |
| Hagii, J | 1 |
| Kamada, T | 1 |
| Yasujima, M | 1 |
| Tomita, H | 1 |
| Magota, K | 1 |
| Okumura, K | 1 |
| Kima, KY | 1 |
| Park, SY | 2 |
| Lee, WS | 2 |
| Yamazaki, M | 1 |
| Kimura, Y | 2 |
| Iwata, M | 1 |
| Stansby, GP | 2 |
| Liao, JK | 1 |
| Nishimura, K | 1 |
| Ishigooka, J | 1 |
| Imamura, Y | 1 |
| Ihara, S | 1 |
| Mikuni, M | 1 |
| Fukuda, M | 1 |
| Oshima, A | 1 |
| Sakai, T | 1 |
| Kumano, T | 1 |
| Mashima, T | 1 |
| Takeyoshi, H | 1 |
| Ida, I | 1 |
| Ikeda, K | 1 |
| Fujita, Y | 1 |
| Lin, JX | 1 |
| Takahashi, R | 1 |
| Li, Z | 1 |
| Gao, X | 1 |
| Fan, D | 1 |
| Wong, K | 1 |
| Lu, C | 1 |
| Xiao, J | 1 |
| Kim, CD | 1 |
| Nishi, T | 1 |
| Nakagawa, K | 1 |
| Yamaya, M | 1 |
| Yanai, M | 1 |
| Ohrui, T | 1 |
| Arai, H | 1 |
| Sekizawa, K | 1 |
| Sasaki, H | 1 |
| Liu, Y | 1 |
| Shakur, Y | 1 |
| Yoshitake, M | 1 |
| Kambayashi Ji, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: A Phase Ⅱa,Prospective,Multicenter,Randomized, Double-blind,Placebo-controlled Parallel Tri[NCT05836766] | Phase 2 | 120 participants (Anticipated) | Interventional | 2023-06-05 | Recruiting | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin[NCT00234065] | Phase 4 | 2,800 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke[NCT00272454] | Phase 4 | 468 participants (Anticipated) | Interventional | 2006-01-31 | Completed | ||
| Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020] | Phase 3 | 720 participants | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 13 |
| Aspirin | 13 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 138 |
| Aspirin | 186 |
The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 23 |
| Aspirin | 57 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 86 |
| Aspirin | 103 |
(NCT00234065)
Timeframe: From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 72 |
| Aspirin | 88 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints. (NCT00234065)
Timeframe: From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 82 |
| Aspirin | 119 |
44 reviews available for cilostazol and Apoplexy
| Article | Year |
|---|---|
Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.
Topics: Cilostazol; Evidence-Based Medicine; Humans; Ischemic Stroke; Phosphodiesterase 3 Inhibitors; Second | 2021 |
Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications.
Topics: Animals; Cilostazol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2022 |
Antiplatelet Use in Ischemic Stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Network Meta-Analysis; Pl | 2022 |
Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Network Meta-Analysis; Platelet | 2023 |
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions.
Topics: Cerebral Revascularization; Cilostazol; Humans; Moyamoya Disease; Platelet Aggregation Inhibitors; S | 2023 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
Topics: Cilostazol; Cognitive Dysfunction; Fibrinolytic Agents; Humans; Phosphodiesterase 3 Inhibitors; Seco | 2020 |
Cilostazol for secondary stroke prevention: systematic review and meta-analysis.
Topics: Brain Ischemia; Cilostazol; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized Control | 2021 |
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Topics: Adenosine; Cilostazol; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Stroke; T | 2022 |
Cilostazol for intermittent claudication.
Topics: Aged; Bias; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pento | 2021 |
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor | 2013 |
Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke.
Topics: Aspirin; Cilostazol; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Tetrazol | 2013 |
Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Disease Progression; Humans; Incidenc | 2013 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Cilostazol for intermittent claudication.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifyll | 2014 |
The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis.
Topics: Acute Disease; Asian People; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Chronic Disease; Cil | 2014 |
Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis.
Topics: Aged; Brain Ischemia; Cilostazol; Databases, Factual; Female; Fibrinolytic Agents; Humans; Male; Mid | 2015 |
Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting.
Topics: Angioplasty; Cardiovascular Agents; Carotid Stenosis; Chi-Square Distribution; Cilostazol; Humans; M | 2016 |
Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis.
Topics: Asian People; Brain Ischemia; Cilostazol; Humans; Ischemic Attack, Transient; Network Meta-Analysis; | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives.
Topics: Animals; Blood-Brain Barrier; Cilostazol; Humans; Mice; Phosphodiesterase 3 Inhibitors; Rats; Stroke | 2016 |
[Peripheral arterial disease with lower limb claudication: Medical treatment].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Cilostazol; Comorbidity; Diabetes Complications; Dr | 2009 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma | 2011 |
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Endothelium, Vascular; Humans; Intracrania | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clop | 2011 |
Current management of symptomatic intracranial stenosis.
Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Patholog | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
[Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients].
Topics: Aspirin; Cilostazol; Gastrointestinal Hemorrhage; Humans; Japan; Platelet Aggregation Inhibitors; Ra | 2010 |
[New clinical concept and therapeutic strategy for TIA].
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Humans; Ischemic Attac | 2010 |
Use of cilostazol for secondary stroke prevention: an old dog with new tricks?
Topics: Cilostazol; Humans; Platelet Aggregation Inhibitors; Stroke; Tetrazoles | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study.
Topics: Cilostazol; Humans; Incidence; Japan; Platelet Aggregation Inhibitors; Randomized Controlled Trials | 2005 |
Cilostazol: therapeutic potential against focal cerebral ischemic damage.
Topics: Animals; Brain Ischemia; Cilostazol; Humans; Neuroprotective Agents; Phosphodiesterase Inhibitors; S | 2006 |
Cilostazol for peripheral arterial disease.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
[Organic cause of emotional depression].
Topics: Animals; Brain; Cerebrovascular Circulation; Cilostazol; Depressive Disorder, Major; Glucose; Humans | 2007 |
Cilostazol for peripheral arterial disease.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral | 2008 |
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.
Topics: Cerebrovascular Disorders; Chronic Disease; Cilostazol; Clinical Trials as Topic; Humans; Ischemic A | 2008 |
[Research and development of cilostazol: an antiplatelet agent].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterial Occlusive Diseases; Cilostazol; Clinical Tria | 2000 |
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Oc | 2001 |
42 trials available for cilostazol and Apoplexy
| Article | Year |
|---|---|
Prior intracerebral hemorrhage and white matter hyperintensity burden on recurrent stroke risk.
Topics: Aged; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 2021 |
Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Intracranial Arteriosclerosis; Platelet Aggregation I | 2021 |
Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhi | 2022 |
Tachycardia Changes Increase Neurological Deterioration in Patients with Acute Non-Cardioembolic Stroke: An ADS Post-Hoc Analysis.
Topics: Aspirin; Cilostazol; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prospective | 2023 |
Cilostazol improves endothelial function in patients with ischemic stroke: A randomized controlled single-center study with flow-mediated dilation technique.
Topics: Brain Ischemia; Cilostazol; Dilatation; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; St | 2022 |
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi | 2023 |
Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com.
Topics: Cilostazol; Drug Therapy, Combination; Female; Humans; Ischemic Stroke; Male; Platelet Aggregation I | 2023 |
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850).
Topics: Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Middle Aged; Prospective | 2023 |
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2023 |
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Topics: Aged; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Male; Middle Aged; Quality of Life | 2023 |
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke.
Topics: Aged; Atrial Fibrillation; Cilostazol; Humans; Male; Prospective Studies; Retrospective Studies; Ris | 2020 |
Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middl | 2017 |
Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study.
Topics: Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Common; Carotid Inti | 2017 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method | 2018 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; | 2019 |
Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset.
Topics: Aged; Aspirin; Cilostazol; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregatio | 2019 |
Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial.
Topics: Aged; Cilostazol; Disease Progression; Drug Therapy, Combination; Female; Fibrinolytic Agents; Free | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Protein; Cilostazol; Disease Progression; Doub | 2014 |
The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
Topics: Aspirin; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hu | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; | 2015 |
Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.
Topics: Adult; Anticholesteremic Agents; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cognition Disorder | 2016 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati | 2017 |
Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke.
Topics: Aged; Aspirin; Cilostazol; Cross-Over Studies; Deglutition Disorders; Double-Blind Method; Humans; M | 2008 |
Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
Topics: Aspirin; Bleeding Time; Brain Ischemia; Cilostazol; Double-Blind Method; Drug Resistance; Drug Thera | 2010 |
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Cilostazol; Double-Blind Method; Female; Follow-Up Studie | 2010 |
Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients.
Topics: Adult; Aged; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation; Cilostazol; Female; Hem | 2011 |
Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
Topics: Aged; Aspirin; Cilostazol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage | 2011 |
Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.
Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Cilostazol; Clopidogrel; Death; Drug Antagonism; Dru | 2011 |
Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2012 |
Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combinati | 2011 |
Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Brain Stem; Cerebellum; Cerebrovascular Circulatio | 2012 |
Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions.
Topics: Aspirin; Blood Pressure; Brain; Brain Diseases; Cerebral Hemorrhage; Cilostazol; Disease Progression | 2012 |
Effect of cilostazol in the treatment of acute ischemic stroke in the lenticulostriate artery territory.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cilostazol; Double-Blind Method; Drug Therapy, Combination; | 2013 |
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cilostazol; Double-Blind Method; Female; | 2008 |
Antithrombotic therapy for prevention of pneumonia.
Topics: Aged; Cerebral Infarction; Cilostazol; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Pn | 2001 |
48 other studies available for cilostazol and Apoplexy
| Article | Year |
|---|---|
Our Efforts for Ideal Stroke Prevention and Treatment in Japan.
Topics: Cilostazol; Humans; Japan; Platelet Aggregation Inhibitors; Primary Prevention; Secondary Prevention | 2022 |
Advancing Secondary Stroke Prevention Strategies: Optimal Timing of Dual Antiplatelet Therapy With Cilostazol.
Topics: Cilostazol; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke | 2022 |
Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Cost-Benefit Analysis; Humans; Markov Chains; Platelet Aggregation | 2022 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis.
Topics: Blood Pressure; Cilostazol; Humans; Ischemic Attack, Transient; Ischemic Stroke; Recurrence; Stroke | 2023 |
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagi | 2023 |
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2020 |
Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports.
Topics: Aged; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; | 2020 |
Response by Doubal et al to Letter Regarding Article, "Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis".
Topics: Cilostazol; Cognitive Dysfunction; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; St | 2020 |
Letter by Xu et al Regarding Article, "Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis".
Topics: Cilostazol; Cognitive Dysfunction; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; St | 2020 |
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
Topics: Aged; Aspirin; Cilostazol; Disease Progression; Dual Anti-Platelet Therapy; Female; Humans; Japan; M | 2021 |
Microbleeds and clinical outcome in acute mild stroke patients treated with antiplatelet therapy: ADS post-hoc analysis.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cilostazol; Dual Anti-Platelet Therapy; Female; Humans; Magnetic | 2021 |
Cilostazol is Effective to Prevent Stroke-Associated Pneumonia in Patients Receiving Tube Feeding.
Topics: Aged; Aged, 80 and over; Cilostazol; Enteral Nutrition; Female; Humans; Male; Platelet Aggregation I | 2018 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
Recurrent cerebral microbleeds with acute stroke symptoms: A case report.
Topics: Aged; Basal Ganglia Cerebrovascular Disease; Brain; Cerebral Hemorrhage; Cilostazol; Cognitive Dysfu | 2018 |
Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function.
Topics: Animals; Blood Platelets; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Disease Models, Animal; M | 2019 |
The uncertain role for phosphodiesterase inhibitors in stroke prevention.
Topics: Brain Ischemia; Cilostazol; Humans; Japan; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibi | 2019 |
Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Cohort Studies; Female; Humans; Longitudinal Studies; Male; | 2013 |
Cilostazol for peripheral arterial disease could reduce stroke risk?
Topics: Cilostazol; Female; Humans; Male; Peripheral Arterial Disease; Stroke; Tetrazoles; Vasodilator Agent | 2013 |
Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation.
Topics: Animals; Antigens; Aspirin; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Disease Models, An | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
The effect of acute medication with cilostazol, an anti-platelet drug, on the outcome of small vessel brain infarction.
Topics: Aged; Aged, 80 and over; Brain Infarction; Cilostazol; Disease Progression; Female; Humans; Japan; M | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.
Topics: Cilostazol; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Risk Factors; Stroke; | 2014 |
Cilostazol and outcome in outpatients with peripheral artery disease.
Topics: Aged; Cilostazol; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intermittent Claudication; Male; | 2014 |
Cilostazol research in Asia: can it be applied to European and American patients?
Topics: Asia; Cilostazol; Europe; Hemorrhage; Humans; Intracranial Arteriosclerosis; Phosphoric Diester Hydr | 2015 |
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti | 2015 |
Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
Topics: Aged; Cilostazol; Disease-Free Survival; Female; Humans; Kidney Diseases; Male; Middle Aged; Periphe | 2016 |
Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cilostazol; Corpus Striatum; Cyclic AMP Response Element | 2016 |
Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke.
Topics: Animals; Antidepressive Agents; Aripiprazole; Atrophy; Behavior, Animal; Brain; Cell Differentiation | 2017 |
Cilostazol reduces restenosis after carotid artery stenting.
Topics: Aged; Angioplasty; Carotid Artery Diseases; Cilostazol; Drug Therapy, Combination; Female; Humans; M | 2010 |
From bench to bedside: report of the Sixth International Stroke Summit, Nanjing, China, July 9-11, 2010.
Topics: Asia; Aspirin; China; Cilostazol; Endarterectomy; Humans; Platelet Aggregation Inhibitors; Stents; S | 2010 |
What are the therapeutic options for strokes secondary to intracranial large artery stenosis?
Topics: Anticoagulants; Aspirin; Cilostazol; Evidence-Based Medicine; Humans; Intracranial Arteriosclerosis; | 2011 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B | 2010 |
Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay.
Topics: Aged; Blood Coagulation Tests; Blood Platelets; Carotid Artery Diseases; Cilostazol; Clopidogrel; Dr | 2011 |
Cilostazol in patients with ischemic stroke.
Topics: Animals; Brain Ischemia; Cilostazol; Disease Models, Animal; Humans; Phosphodiesterase 3 Inhibitors; | 2011 |
Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Cilostazol; Endothel | 2011 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
A new antiplatelet agent cilostazol--what is the evidence for its use and tolerability?
Topics: Aspirin; Cilostazol; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Randomized Co | 2012 |
Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients.
Topics: Adult; Aged; Analysis of Variance; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholester | 2013 |
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic | 2014 |
Coupling factor 6 enhances the spontaneous microaggregation of platelets by decreasing cytosolic cAMP irrespective of antiplatelet therapy.
Topics: Aged; Area Under Curve; ATP Synthetase Complexes; Blotting, Western; Cholera Toxin; Cilostazol; Cycl | 2013 |
New modalities and aspects of antiplatelet therapy for stroke prevention.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi | 2006 |
Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy?
Topics: Aspirin; Brain Infarction; Cilostazol; Humans; Incidence; Japan; Myocardial Ischemia; Platelet Aggre | 2006 |
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Chronic Disease; Cilostazol; Female; Follow-Up Studies; H | 2006 |
Cilostazol, a cAMP phosphodiesterase 3 inhibitor, in the treatment of poststroke depression.
Topics: Cilostazol; Depressive Disorder; Humans; Infarction, Middle Cerebral Artery; Male; Middle Aged; Phos | 2007 |
Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats.
Topics: Actins; Analysis of Variance; Animals; Blood Pressure; Blood Vessels; Cilostazol; Male; Muscle, Smoo | 2008 |
Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Data Interpretation, Statistical; Dose-Res | 2008 |